


AstraZeneca today announced the US availability of ZEGFROVYÂ (sunvozertinib) for the treatment of adults with locally advanced or metastatic non-small cell lun

ESMO 2026 Preview | Mabwell to Present Clinical Results for Nectin-4-Targeting ADC 9MW2821 in ADC-Pretreated Triple-Negative Breast CancerPR NewswireSHANGHAI, O

VANCOUVER, British Columbia, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Equity Insider News Commentary - Copper exploration in British Columbia increasingly means looking for what cannot be seen at surface, and explorers are leaning on geophysics before they commit to a drill program.

CHICAGO--(BUSINESS WIRE)--Coeur Mining, Inc. (“Coeur” or the “Company”) (NYSE, TSX: CDE) today announced that it will report its third quarter 2026 operational and financial results after the New York Stock Exchange and Toronto Stock Exchange close for trading on Wednesday, November 4, 2026. The Company will be hosting a conference call at 11:00 a.m. Eastern Time (10:00 a.m. Central Time) on Thursday, November 5, 2026. Hosting the call will be Mitchell J. Krebs, Chairman, President and Chief Ex.

Corient Private Wealth LP lowered its stake in Coeur Mining, Inc. (NYSE: CDE) by 92.5% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 12,132 shares of the basic materials company's stock after selling 150,083 shares during the period. Corient Private Wealth LP's holdings

Coeur Mining (NYSE: CDE) expects production to accelerate in the second half of 2026 as recently acquired Canadian operations ramp up and several existing mines benefit from expansion projects, President and CEO Mitchell Krebs said during a company event. Krebs said the company closed its New Gold transaction in late March, adding the Rainy River mine

Coeur Mining NYSE: CDE expects production to accelerate in the second half of 2026 as recently acquired Canadian operations ramp up and several existing mines benefit from expansion projects, President and CEO Mitchell Krebs said during a company event.